Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
LY4302814 · 1 trial · 1 indication
| Arm | Type | Description |
|---|---|---|
| LY4302814 IV | EXPERIMENTAL | LY4302814 administered intravenously (IV) |
| Placebo IV | PLACEBO_COMPARATOR | Placebo administered IV |
| LY4302814 SC | EXPERIMENTAL | LY4302814 administered subcutaneously (SC) |
| Placebo SC | PLACEBO_COMPARATOR | Placebo administered SC |
| Name | Type | Description |
|---|---|---|
| LY4302814 | DRUG | Administered SC |
| Placebo | DRUG | Administered SC |
Inclusion Criteria: * Are overtly healthy as determined by medical evaluation. * Have clinical laboratory test results within the normal range for the population or investigative site or with abnormalities deemed not clinically significant by the investigator. * Have a body weight of 45 kilograms (...
LY4302814 is an investigational small molecule being studied in healthy participants. It is currently in Phase 1 clinical development, with a trial evaluating its safety and tolerability in healthy volunteers. The drug is not approved for any condition and is still in early-stage clinical testing.
The molecular target of LY4302814 has not been disclosed. It is a small molecule being developed by Eli Lilly and Company, but its specific mechanism of action is not publicly available at this time.
LY4302814 is being developed by Eli Lilly and Company, a pharmaceutical company traded on the New York Stock Exchange under the ticker symbol LLY. The company is conducting a Phase 1 clinical trial of the drug in healthy participants.
LY4302814 is in Phase 1 clinical development. It is an investigational drug being studied in a single active trial that is currently recruiting participants. The drug has not been approved by regulatory authorities and is still in early-stage testing.
LY4302814 is being studied in a Phase 1 clinical trial with the identifier NCT07566338, titled 'A Study of LY4302814 in Healthy Participants.' The trial is recruiting 150 healthy volunteers in the United States and Singapore, with participants aged 18 years and older.
LY4302814 is not FDA approved. It is an investigational drug currently in Phase 1 clinical trials, meaning it has not yet been evaluated for safety and efficacy in large patient populations. The drug is still in early-stage development and has not received regulatory approval.